Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with alternating XELIRI and XELOX as first-line therapy for metastatic colorectal cancer
2011-003137-33Phase 2Completed
- Sponsor
- Pia österlund and Helena Isoniemi
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, capecitabine in metastatic colorectal adenocarcinoma (mCRC), sponsored by Pia österlund and Helena Isoniemi. Started Sep 2011; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2011-003137-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003137-33.